|
市場調査レポート
商品コード
1671856
紅斑性肢痛症治療市場：タイプ別、用途別、投与経路別、薬剤別、流通チャネル別、地域別Erythromelalgia Treatment Market, By Type, By Application, By Route of Administration, By Drugs, By Distribution Channel, By Geography |
||||||
カスタマイズ可能
|
|||||||
| 紅斑性肢痛症治療市場：タイプ別、用途別、投与経路別、薬剤別、流通チャネル別、地域別 |
|
出版日: 2025年02月26日
発行: Coherent Market Insights
ページ情報: 英文 150 Pages
納期: 2～3営業日
|
- 全表示
- 概要
- 目次
紅斑性肢痛症治療の世界市場規模は2025年に25億3,000万米ドルと推定され、2032年には36億8,000万米ドルに達すると予測され、2025年から2032年までのCAGRは5.5%で推移すると予測されています。
| レポート範囲 | レポート詳細 | ||
|---|---|---|---|
| 基準年 | 2024 | 2025年の市場規模 | 25億3,000万米ドル |
| 実績データ | 2020年から2024年まで | 予測期間 | 2025年から2032年 |
| 予測期間：2025年～2032年 CAGR： | 5.50% | 2032年の価値予測 | 36億8,000万米ドル |
紅斑性肢痛症は、四肢、特に足と下肢の強い灼熱痛、発赤、皮膚温上昇を特徴とするまれな疾患です。紅斑性肢痛症の正確な原因は不明です。しかし、皮膚の血管や痛みの信号を脳に伝える神経の異常が原因と考えられています。労作や体温の上昇によって症状が悪化することが多いです。紅斑性骨髄痛の治療法は確立されていないため、治療の目標は症状を管理し、再燃を防ぐことです。紅斑性肢痛症治療の世界市場は、主にこの疾患の有病率の増加と、新規でより効果的な治療オプションの開発のための研究開発努力の増加によって牽引されています。
市場力学：
紅斑性肢痛症治療の世界市場を促進する主な要因としては、希少疾患の有病率の増加、利用可能な治療オプションに関する認知度の向上、多くの国におけるヘルスケア支出の増加などが挙げられます。さらに、より的を絞った新しい治療薬の開発研究が進んでおり、製品パイプラインが拡大しています。このことは、予測期間中の市場成長を押し上げると予想されます。しかし、承認された治療ガイドラインの欠如や、この疾患の希少性に起因する診断率の低さが、市場成長の課題となっています。また、治療費の高さも新興国市場への浸透を制限しています。プラス面では、市場参入企業による臨床試験へのさまざまな戦略的取り組みが、将来の市場機会として大きな可能性を秘めています。
本調査の主な特徴
本レポートでは、世界の紅斑性肢痛症治療市場を詳細に分析し、2024年を基準年とした予測期間（2025-2032年）の市場規模および複合年間成長率（CAGR%）を掲載しています。
また、さまざまなセグメントにわたる潜在的な収益機会を明らかにし、この市場の魅力的な投資提案マトリクスについて解説しています。
また、市場促進要因、抑制要因、機会、新製品の上市や承認、市場動向、地域別の展望、主要企業が採用する競争戦略などに関する主要考察も提供しています。
世界の紅斑性肢痛症治療市場における主要企業プロファイルを、企業ハイライト、製品ポートフォリオ、主要ハイライト、業績、戦略などのパラメータに基づいて掲載しています。
本調査の対象となる主要企業には、Teva Pharmaceutical Industries Ltd、Biogen、Pfizer Inc、Akorn、Novartis AG、Galderma SA、Acorda Therapeutics Inc、AbbVie、Amneal Pharmaceuticals LLC、Xenon Pharmaceuticals Inc、Ligand Pharmaceuticals Incorporated、Zydus Cadila、ANI Pharmaceuticals Inc、Lupin Limited、Bausch Healthなどがあります。
本レポートからの洞察により、マーケティング担当者や企業の経営陣は、将来の製品発売、タイプアップ、市場拡大、マーケティング戦術に関する情報に基づいた意思決定を行うことができます。
世界の紅斑性肢痛症治療市場レポートは、投資家、サプライヤー、製品メーカー、販売業者、新規参入者、財務アナリストなど、この業界の様々な利害関係者を対象としています。
利害関係者は、世界の紅斑性肢痛症治療市場の分析に使用される様々な戦略マトリックスを通じて、意思決定を容易にすることができます。
目次
第1章 調査の目的と前提条件
- 調査目的
- 前提条件
- 略語
第2章 市場の展望
- レポートの説明
- 市場の定義と範囲
- エグゼクティブサマリー
第3章 市場力学、規制、動向分析
- 市場力学
- 促進要因
- 抑制要因
- 機会
- 影響分析
- 主な発展
- 規制シナリオ
- 製品の発売/承認
- PEST分析
- PORTERの分析
- 合併と買収のシナリオ
- 業界動向
第4章 世界の紅斑性肢痛症治療市場、タイプ別、2020年～2032年
- 薬剤療法
- 非薬剤療法
第5章 世界の紅斑性肢痛症治療市場、用途別、2020年～2032年
- 原発性紅斑痛症
- 二次性紅斑痛
第6章 世界の紅斑性肢痛症治療市場、投与経路別、2020年～2032年
- 経口
- 局所
- 吸入
第7章 世界の紅斑性肢痛症治療市場、薬剤別、2020年～2032年
- リドカイン
- アムロジピン
- ガバペンチン
- アミトリプチリン
- カプサイシン
- ジクロフェナク
- ブリモニジン
- ミソプロストール
- その他
第8章 世界の紅斑性肢痛症治療市場、流通チャネル別、2020年～2032年
- 病院薬局
- 小売薬局
- オンライン薬局
第9章 世界の紅斑性肢痛症治療市場、地域別、2020年～2032年
- 北米
- ラテンアメリカ
- 欧州
- アジア太平洋
- 中東
- アフリカ
第10章 競合情勢
- Teva Pharmaceutical Industries Ltd
- Biogen
- Pfizer Inc
- Akorn
- Novartis AG
- Galderma SA
- Acorda Therapeutics Inc
- AbbVie
- Amneal Pharmaceuticals LLC
- Xenon Pharmaceuticals Inc
- Ligand Pharmaceuticals Incorporated
- Zydus Cadila
- ANI Pharmaceuticals Inc
- Lupin Limited
- Bausch Health
第11章 アナリストの推奨事項
- 運命の輪
- アナリストの見解
- 一貫した機会マップ
第12章 参考文献と調査手法
- 参考文献
- 調査手法
- 出版社について
Global Erythromelalgia Treatment Market is estimated to be valued at US$ 2.53 Bn in 2025 and is expected to reach US$ 3.68 Bn by 2032, growing at a compound annual growth rate (CAGR) of 5.5% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | US$ 2.53 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 5.50% | 2032 Value Projection: | US$ 3.68 Bn |
Erythromelalgia is a rare disease characterized by intense burning pain, redness, and increased skin temperature in the extremities, especially the feet and lower legs. The exact cause of erythromelalgia is unknown. However, it is believed to be caused due to abnormalities in the blood vessels of the skin and nerves that communicate pain signals to the brain. Symptoms often worsen with physical exertion or increases in body temperature. As there is no known cure for erythromelalgia, the goal of treatment is to manage symptoms and prevent flare-ups. The global erythromelalgia treatment market is primarily driven by the growing prevalence of the disease and increasing R&D efforts for development of novel and more effective treatment options.
Market Dynamics:
The key drivers fueling the global erythromelalgia treatment market include growing prevalence of the rare disease, rising awareness about available treatment options, and increasing healthcare expenditure in many countries. Additionally, ongoing research for development of new and more targeted treatment drugs is expanding the product pipeline. This is expected to boost the market growth during the forecast period. However, lack of approved treatment guidelines and poor diagnosis rate owing to the rarity of the disease pose challenges to market growth. High cost of treatment also restricts market penetration in developing regions. On the positive side, various strategic initiatives by market players for clinical trials hold significant potential for future market opportunities.
Key Features of the Study:
This report provides in-depth analysis of the global erythromelalgia treatment market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global erythromelalgia treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd, Biogen, Pfizer Inc, Akorn, Novartis AG, Galderma SA, Acorda Therapeutics Inc, AbbVie, Amneal Pharmaceuticals LLC, Xenon Pharmaceuticals Inc, Ligand Pharmaceuticals Incorporated, Zydus Cadila, ANI Pharmaceuticals Inc, Lupin Limited, and Bausch Health
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global erythromelalgia treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global erythromelalgia treatment market
Market Segmentation
- Type Insights (Revenue, USD Bn, 2020 - 2032)
- Drug Therapy
- Non-Pharmacological Therapies
- Application Insights (Revenue, USD Bn, 2020 - 2032)
- Primary Erythromelalgia
- Secondary Erythromelalgia
- Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
- Oral
- Topical
- Inhalation
- Drugs Insights (Revenue, USD Bn, 2020 - 2032)
- Lidocaine
- Amlodipine
- Gabapentin
- Amitriptyline
- Capsaicin
- Diclofenac
- Brimonidine
- Misoprostol
- Others
- Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
- Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Teva Pharmaceutical Industries Ltd
- Biogen
- Pfizer Inc
- Akorn
- Novartis AG
- Galderma SA
- Acorda Therapeutics Inc
- AbbVie
- Amneal Pharmaceuticals LLC
- Xenon Pharmaceuticals Inc
- Ligand Pharmaceuticals Incorporated
- Zydus Cadila
- ANI Pharmaceuticals Inc
- Lupin Limited
- Bausch Health
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Erythromelalgia Treatment Market, By Type
- Global Erythromelalgia Treatment Market, By Application
- Global Erythromelalgia Treatment Market, By Route of Administration
- Global Erythromelalgia Treatment Market, By Drugs
- Global Erythromelalgia Treatment Market, By Distribution Channel
- Global Erythromelalgia Treatment Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Erythromelalgia Treatment Market, By Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Drug Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Non-Pharmacological Therapies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Global Erythromelalgia Treatment Market, By Application, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Primary Erythromelalgia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Secondary Erythromelalgia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Erythromelalgia Treatment Market, By Route of Administration, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Topical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Inhalation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Erythromelalgia Treatment Market, By Drugs, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Lidocaine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Amlodipine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Gabapentin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Amitriptyline
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Capsaicin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Diclofenac
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Brimonidine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Misoprostol
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global Erythromelalgia Treatment Market, By Distribution Channel, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Retail pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
9. Global Erythromelalgia Treatment Market, By Region, 2020 - 2032, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drugs, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drugs, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drugs, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drugs, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drugs, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drugs, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
10. Competitive Landscape
- Teva Pharmaceutical Industries Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Biogen
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Akorn
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Galderma SA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Acorda Therapeutics Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amneal Pharmaceuticals LLC
- Xenon Pharmaceuticals Inc
- Ligand Pharmaceuticals Incorporated
- Zydus Cadila
- ANI Pharmaceuticals Inc
- Lupin Limited
- Bausch Health
11. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
12. References and Research Methodology
- References
- Research Methodology
- About us
